Introduction to the Abortion Pill Lawsuit
Texas and Florida have launched the latest lawsuit seeking to restrict access to the abortion pill mifepristone, following the U.S. Food and Drug Administration’s recent approval of a new generic version.
In the lawsuit, filed late Tuesday in Wichita Falls, Texas, federal court, the states’ Republican attorneys general argued that the FDA has failed to thoroughly evaluate the drug’s safety and effectiveness since its initial approval in 2000 and disregarded the risks to the women who take it.
“These are tragic but predictable consequences of prioritizing politics over public health,” the states said in the complaint.
Related
The FDA’s Sept. 30 approval of Evita Solutions’ generic version of mifepristone by an agency overseen by Republican President Donald Trump’s administration has fueled outrage among conservatives. U.S. Health Secretary Robert F. Kennedy Jr. at the time said the agency is legally required to approve generics that are identical to their brand-name counterparts.
Business Briefing
The Lawsuit and Its Claims
The lawsuit challenges the initial 2000 approval and approval of Evita’s generic. The states also claim that regulations adopted under Democratic former Presidents Barack Obama and Joe Biden expanding access to mifepristone are unlawful. The lawsuit alleges that the FDA’s actions were arbitrary and capricious, contrary to federal law or beyond the agency’s powers in violation of the federal Administrative Procedure Act.
The FDA did not immediately respond to a request for comment. Evita’s website says it “believes that all people should have access to safe, affordable, high-quality, effective, and compassionate healthcare, including abortion care.”
Understanding Mifepristone and Its Use
Two drug regimen
Mifepristone is the first pill, followed by the drug misoprostol, used for medication abortion in the first 10 weeks of pregnancy, and is used in more than 60% of U.S. abortions.
The claims in the new lawsuit are similar to those made in a separate case by Missouri, Kansas and Idaho. Texas, Florida and Louisiana had sought to join that case, but in September U.S. District Judge Matthew Kacsmaryk in Amarillo said that request was moot when he transferred the lawsuit to St. Louis federal court.
Prior Lawsuits and Court Decisions
That lawsuit was first filed in 2022 by a group of anti-abortion groups and doctors, but the U.S. Supreme Court in 2024 found they did not have the necessary legal standing to challenge the FDA’s regulation of mifepristone.
The Supreme Court overturned a 5th U.S. Circuit Court of Appeals decision that had rolled back FDA regulations easing how the drug is prescribed and distributed. The 5th Circuit, which would hear any appeals in the lawsuit by Texas and Florida, had also ruled at the time that a challenge to the 2000 approval of mifepristone was untimely.
Missouri, Kansas and Idaho, which had intervened in the case, dropped the claim about the 2000 approval but pressed forward with arguments that the FDA acted improperly when it eased restrictions on mifepristone, including by allowing it to be prescribed remotely and dispensed by mail. They have moved to amend the lawsuit to also challenge the recent approval of Evita’s generic.
The case is Florida vs. U.S. Food and Drug Administration, U.S. District Court for the Northern District of Texas, No.7:25-cv-00126.
Conclusion
The lawsuit by Texas and Florida against the FDA regarding the abortion pill mifepristone is a significant development in the ongoing debate over abortion access in the United States. The case challenges not only the recent approval of a generic version of mifepristone but also the initial approval of the drug in 2000 and subsequent regulatory changes that expanded access to it. As the legal proceedings unfold, the outcome will have important implications for women’s health and reproductive rights.
Frequently Asked Questions
Q: What is mifepristone, and how is it used?
A: Mifepristone is a medication used for abortion in the first 10 weeks of pregnancy. It is taken in combination with another drug called misoprostol.
Q: What is the lawsuit by Texas and Florida about?
A: The lawsuit challenges the FDA’s approval of mifepristone, including the initial approval in 2000 and the recent approval of a generic version. The states claim that the FDA failed to properly evaluate the drug’s safety and effectiveness.
Q: What are the potential implications of the lawsuit?
A: The outcome of the lawsuit could affect access to abortion services in the United States, particularly for those who rely on medication abortion. A ruling in favor of the states could restrict access to mifepristone, while a ruling in favor of the FDA could uphold the current regulatory framework.
Q: What is the current status of the lawsuit?
A: The lawsuit is ongoing, with the case filed in the U.S. District Court for the Northern District of Texas. The court will hear arguments and make a decision on the merits of the case.
